WALL, NJ — (Marketwired) — 05/06/13 — BIO-key International, Inc. (OTCQB: BKYI), a global leader in fingerprint biometric identification solutions, advanced mobile credentialing and positive patient identification technologies, today reported that Miller-Keystone Blood Center (MKBC), has selected BIO-key-s TruDonor to enhance the security and convenience of positive donor identification at their centers. Miller-Keystone Blood Center, serves as the only blood provider to 25 hospitals in Berks, Bucks, Carbon, Chester, Lehigh, Luzerne, Montgomery, Northampton, Philadelphia, Schuylkill (PA), as well as Hunterdon and Warren (NJ) counties. MKBC is one of the nation-s most highly regarded and experienced blood centers. MKBC is also a member of America-s Blood Centers (ABC), a national network of independent, non-profit community blood centers that provides approximately 60% of the blood products transfused in the United States.
“We are thrilled to welcome Miller-Keystone to our growing family of blood center customers,” said Jim Sullivan, BIO-key Vice President of Strategy and Business Development. “By leveraging BIO-key to automate the positive ID of their donors and detect duplicate donor records before they are created, they have enhanced the safety and security of the donor collection process, while reducing donor check-in to a two-second operation at their registration desk. The payback is immediate and ongoing,” added Sullivan.
“Miller-Keystone Blood Center is pleased to be working with BIO-key to help increase safety and convenience for our donors as they move through the registration process,” said J. Michael Lee, DBA, FACHE, President-CEO, Miller-Keystone Blood Center. “The security of donor information is of the utmost importance to our blood center and the added benefits that will be realized at the time of registration will no doubt be appreciated by donors and staff alike. We looked at many options for achieving a positive, but streamlined, donor identification process, and feel that BIO-key is revolutionizing the way donors and patients will check in for years to come. This investment in technology will serve Miller-Keystone hospital clients and donors alike.”
“BIO-key is the leading provider of innovative, cost efficient donor ID solutions for blood centers and transfusion facilities,” said Mike DePasquale, CEO. “We have deployed over three million donor identification licenses across our blood center customers to meet the FDA-s strict requirement for positive identification. Our solutions make the donor experience simple and easy while increasing the safety of our nation-s blood supply. BIO-key-s experience in this significant market demonstrates our ability to deliver robust patient ID solutions for our hospital customers as that demand emerges,” added DePasquale.
Established in 1971, Miller-Keystone Blood Center (MKBC) is a not-for-profit, 501(c)(3) community organization that serves as the only provider to hospitals in 12 Pennsylvania and New Jersey counties. MKBC-s history of compliance with FDA requirements, combined with its ISO9001:2008 certification demonstrates a commitment to quality and service excellence. In 2012, MKBC scheduled nearly 106,000 donors, collecting more than 90,000 units of blood, which were processed into over 185,000 life-saving blood products. ()
BIO-key International, Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key-s award winning, high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications. Our solutions are used in local embedded OEM products as well as some of the world-s largest identification deployments to improve security, guarantee identity, and help reduce identity theft. BIO-key-s technology is offered directly or by market leading partners around the world. ()
Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management-s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, our ability to attract and retain key personnel. For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see “Risk Factors” in the Company-s Annual Report on Form 10-K for the year ended December 31, 2012 and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
Contacts:
BIO-key International, Inc.
Jay Meier
651-789-6116
You must be logged in to post a comment Login